The COVID-19 pipeline report presents the most recent updates on drug candidates and vaccine candidates that will potentially reach the market in the next 2 years.
As of May 2020, the COVID-19 pipeline remains robust with over 150 therapeutic and Vaccine candidates under development. 150 companies including large scale and small scale companies are participating in the development of treatment and vaccination against novel corona virus infected COVID-19.
The report provides complete details of pipeline drugs including the development phase, companies involved, clinical trial developments, and other details. Further, the report also provides COVID-19 drug development history, latest news, and other developments.
COVID-19 pipeline comprises of 153 drug candidates under development as of April 2020. The pipeline is characterized by the presence of both large scale companies and small players. Large companies including Novartis, Pfizer, Zydus, Roche, Sanofi and GlaxoSmithKline continue to invest in treatment options vaccination candidates.
Among pre-clinical and research phase candidates, several companies are looking for partnering with other companies or universities to advance their research studies.
Interleukin 6 inhibitors' is among the most researched types in the pipeline.
Around 77 of 153 candidates are new molecular entities.
Of the 153 drug candidates in development, 10 drug/vaccine candidates advanced to Phase 3 while 13 candidates are in Phase 2. Five candidates are in Phase 1 and 42 candidates are in the preclinical study phase. Further, the number of drug and vaccine candidates in the research study phase stood at 83.